Author:
Barsukov A V,Glukhovskoy D V,Talantseva M S,Bagaeva Z V,Pronina E V,Zobnina M P,Sveklina T S,Korovin A E
Abstract
Left ventricular hypertrophy (LVH) is one of the cardio-vascular continuum components, determining the prognosis of patient with essential hypertension (EH). Pathogenesis of LVH has a multifactor character. Important role in development of cardiomyocites hypertrophy, Intracardiac fibrosis, left ventricle cavity dilation belongs to renin-angiotensin-aldosteron system (RAAS). Pharmacologic blockade of RAAS composes the basis of therapy, directed to LVH regress. Application of Telmisartan is considered high-reasonable approach to treatment of EH-patient with LVH.
Publisher
LLC Obyedinennaya Redaktsiya